Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010;2010:824813.
doi: 10.1155/2010/824813. Epub 2009 Dec 28.

Influence of Soy Lecithin Administration on Hypercholesterolemia

Free PMC article

Influence of Soy Lecithin Administration on Hypercholesterolemia

Amouni Mohamed Mourad et al. Cholesterol. .
Free PMC article


Recent studies suggest that lecithin-rich diet can modify cholesterol homeostasis and hepatic lipoprotein metabolism. Considering the phytotherapeutic impact of lecithin, this work hypothesizes that lecithin administration in hypercholesterolemic patients may reduce cholesterol concentrations by increasing biliary secretion. Total cholesterol and LDL were evaluated after soy lecithin administration in hypercholesterolemic patients. One soy lecithin capsule (500 mg/RP-Sherer) was administrated daily. One-two months before the treatment beginning, blood samples were collected for total lipids and cholesterol fractions analysis. The results showed a reduction of 40.66% and 42.00% in total cholesterol and of 42.05% and 56.15% in LDL cholesterol after treatment for one and two months, respectively. A significant reduction in total cholesterol and LDL-cholesterol concentrations was observed during the first month of treatment, suggesting that the administration of soy lecithin daily may be used as a supplemental treatment in hypercholesterolemia.


Figure 1
Figure 1
Total cholesterol (CH, mg/dL) and cholesterol concentration in lipoproteins (mg/dL) before and 2 months after placebo administration. The error bars represent statistical significance (P < .001).
Figure 2
Figure 2
Total cholesterol (CH, mg/dL) and cholesterol concentration in lipoproteins (mg/dL) in serum before and after the first and the second months of lecithin administration. * Significant in relation to the period before treatment.

Similar articles

See all similar articles

Cited by 3 articles


    1. Kingsbury KJ, Bondy G. Understanding the essentials of blood lipid metabolism. Progress in Cardiovascular Nursing. 2003;18(1):13–18. - PubMed
    1. Kannel WB, Castelli WP, Gordon T. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Annals of Internal Medicine. 1979;90(1):85–91. - PubMed
    1. Levine GN, Keaney JF, Jr., Vita JA. Medical progress: cholesterol reduction in cardiovascular disease—clinical benefits and possible mechanisms. The New England Journal of Medicine. 1995;332(8):512–521. - PubMed
    1. Lipid Research Clinics Program. The Lipid Research Clinics Program: the lipid Research Clinics primary preventio trial results I and H. The Journal of the American Medical Association. 1984;251:351–374. - PubMed
    1. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering in men with high levels of apolipoprotein B . The New England Journal of Medicine. 1990;323:1290–1298. - PubMed

LinkOut - more resources